3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
43
Dermatologic
14
Gastrointestinal
13
Thoracic
11
Head & Neck
11
Breast
10
Genitourinary
8
Gynecologic
6
Lymphoid
4
CNS
3
Other solid neoplasm
2
Other hematologic neoplasm
1
Endocrine
1
Conditions
Neuroendocrine Tumors
11
Adrenocortical Carcinoma
7
Thyroid Carcinoma, Anaplastic
5
Carcinoma, Neuroendocrine
4
Thyroid Neoplasms
3
Adrenal Cortex Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Small Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Penile Neoplasms
1
Pathologic Processes
1
Parotid Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma
1
Neoplasms, Unknown Primary
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Interventions
Fluorodeoxyglucose F18
3
Doxorubicin
3
Cyclophosphamide
3
surufatinib
2
fludarabine
2
entrectinib
2
Radiotherapy
2
Nivolumab
2
Ifosfamide
2
Filgrastim
2
Drug Therapy
2
Cisplatin
2
tivozanib
1
tislelizumab
1
tipifarnib
1
selpercatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
pembrolizumab
1
milademetan
1
ganitumab
1
fludarabine phosphate
1
entinostat
1
dostarlimab
1
conatumumab
1
cixutumumab
1
cabozantinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
pembrolizumab
×
Endocrine
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled